Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radotinib in Parkinson's Disease
NCT04691661Phase 2Active, not recruiting
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Placebo: Dose escalation with Radotinib HCl: Dose escalation (2 arms). Primary endpoint: Adverse Events at 12 months. Started Sep 2021; status: active, not recruiting.
02
Drugs
radotinib
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04691661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691661.